Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

Pulmonary Function Tests

Pulmonary Function Tests

Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mycophenolate and Azathioprine in Fibrotic Interstitial Lung Disease.

American journal of respiratory and critical care medicine·2026

Same author

Geographical, institutional and workplace variability in genetic evaluation, screening practices, multidisciplinary care, and lung transplantation management for familial interstitial lung disease.

BMC pulmonary medicine·2026

Same author

Longitudinal Mediastinal Lymph Node Dynamics Associate with Mortality and Fibrosis Progression in Fibrotic ILD.

Chest·2026

Same author

Two Blood-based Endotypes Reveal Divergent Clinical Outcomes of Fibrotic Hypersensitivity Pneumonitis.

medRxiv : the preprint server for health sciences·2026

Same author

CTHRC1: a serum biomarker for a pathological fibroblast in IPF.

Thorax·2026

Same author

Performance of Age-Adjusted Whole Genome Sequencing Telomere Length in Idiopathic Pulmonary Fibrosis.

American journal of respiratory and critical care medicine·2026

Search research articles

Related Experiment Video

Updated: Jun 12, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis.

Justin M Oldham¹, Megan L Neely², Daniel M Wojdyla³

¹Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI.

|February 28, 2025

Summary

Even small declines in lung function, such as forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (Dlco), significantly increase mortality risk in idiopathic pulmonary fibrosis (IPF) patients.

Keywords:

interstitial lung disease pulmonary fibrosis respiratory function tests

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Related Experiment Videos

Last Updated: Jun 12, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Area of Science:

Pulmonology
Respiratory Medicine
Clinical Research

Background:

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease characterized by progressive scarring and declining lung function.
High mortality rates underscore the need for accurate prognostic markers in IPF management.

Purpose of the Study:

To investigate the association between specific thresholds of lung function decline and mortality risk in IPF patients.
To determine if declines in forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (Dlco) predict outcomes.

Main Methods:

Analysis of data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (N=1,001).
Cox proportional hazards models assessed the risk of death or lung transplantation following declines in FVC or Dlco (≥2%, ≥5%, ≥10%, and ≥15% for Dlco).
Models were adjusted for key clinical variables including age, sex, BMI, smoking status, and treatment.

Main Results:

All tested thresholds of FVC and Dlco decline were significantly associated with increased risk of death or lung transplantation.
Adjusted analyses revealed that FVC declines of ≥10% predicted a 2.7-fold increased risk.
Dlco declines of ≥15% predicted a 1.9-fold increased risk, with relative declines showing a greater risk increase than absolute declines.

Conclusions:

Even minor decrements in FVC and Dlco serve as crucial prognostic indicators in IPF.
Monitoring lung function decline is essential for risk stratification and management of IPF patients.